Nick.jpg

Principal Investigator:

Dr. Nicholas S.K. Fung, Clinical Assistant Professor

RCT_lab.png

Overview 

The University of Hong Kong Retinal and Macular diseases Clinical Trials Research group is focused on diseases of the retina including those related to diabetes, age related degeneration or vascular occlusions. Previous treatments for such diseases have been limited and often ineffective. With the introduction of anti VEGF, millions of patients worldwide have been successfully treated for their various retinal or macular diseases.
Our group has been closely involved in the testing and introduction of these anti VEGF drugs with some of the largest clinical trials in the world, with a hand in many of the current drugs on the market in Hong Kong today. By bringing in newer, longer lasting, more effective drugs to the patients, we hope to also minimise the treatment burden of the patient. Although the use of these drugs have been shown to be safe and effective, our team continues to also work on optimising the dosage and minimising the side effects by closely working with the network of medical retinal experts worldwide. The landmark clinical trials we have been involved with are listed below which include the testing of current drugs such as ranibizumab (Lucentis), and aflibercept (Eylea) or upcoming drugs such as conbercept, faricimab and abicipar.

Members

Research Staff:

Jaycie Lee - Research Nurse
Degree: Bachelor of Nursing, The Chinese University of Hong Kong

Leung Man Kei - Lead Research Optometrist
Degree: Registered Optometrist (Part 1), BSc (Hons) in Optometry, The Hong Kong Polytechnic University

Stephen Chan - Senior Research Assistant & Orthoptist
Degree: Double Degree in Bachelor of Science and Bachelor of Law from The University of Hong Kong and University of London

Wong Wing Hung Rainbow - Research Optometrist
Degree: Registered Optometrist (Part 1), BSc in Optometry, The Hong Kong Polytechnic University

Lam Liu Miu - Research Assistant
Degree: BSc (Food and Nutritional Science) The University of Hong Kong

Postgraduate Students:

  • Name : Jennifer Tsui, Master of Philosophy (Ophthalmology) candidate

 

Ophthalmologists

  • Professor Lam Wai Ching, Professor, Department of Ophthalmology, University of Hong Kong

  • Dr. Ian YH Wong, Honorary Associate Professor, Department of Ophthalmology, University of Hong Kong

  • Dr. Jeremy Kwok, Clinical Assistant Professor, Department of Ophthalmology, University of Hong Kong

  • Dr. Loraine Chow, Clinical Assistant Professor, Department of Ophthalmology, University of Hong Kong

  • Dr. Bonnie Choy, Clinical Assistant Professor, Department of Ophthalmology, University of Hong Kong

  • Dr. Qing Li, Associate Consultant, Grantham Hospital

  • Dr. Anthony Mak, Resident Specialist, Grantham Hospital

  • Dr. Stephanie Yuk, Resident Specialist, Grantham Hospital

  • Dr. Christie Lun, Resident, Grantham Hospital

 Ongoing Clinical Trials Projects 

Age Related Macular Degeneration (黃斑病變):

  1. Avonelle-X (X/GR42691): A Multicenter, open-label extension study to evaluate the long term safety and tolerability of Faricimab in patients with Neovascular age-related macular degeneration - (Sponsored by Roche Holding AG)

  2. AMGEN (20170542): A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration - (Sponsored by AMGEN Inc)

  3. Everest & Planet follow up study: To determine long-term outcomes, recurrence rates, and treatment needs in PCV - (in collaboration with Singapore Eye Research Institute)

  4. LUCERNE (40844): A phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety of Faricimab in patients with neovascular age-related macular degeneration - (Sponsored by Roche Holding AG)

  5. PANDA: A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration - (Sponsored by Chengdu Kanghong Pharmaceuticals)

Diabetic Macular diseases (糖尿上眼):

  1. RHINE (GR40398): A phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety of RO6867461in patients with diabetic macular edema - (Roche Holding AG)

  2. RHONE X: (GR41987) A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients with Diabetic Macular Edema - (Sponsored by Roche Holding AG)

Retinal Vein occlusion (視網膜血管閉塞):

  1. Balaton (GR41984) A phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety of Faricimab in patients with macular edema secondary to branch retinal vein occlusion - (Sponsored by Roche Holding AG)

  2. Comino (GR41986) A phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety of Faricimab in patients with macular edema secondary to central retinal or hemiretinal vein occlusion - (Sponsored by Roche Holding AG)

Previously completed International multicentered, clinical trials:

  1. VIVID East: A randomized, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macular edema - completed 2016 (Sponsored by Bayer AG)

  2. CEDAR/SEQUOIA: Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration - completed 2019 (Sponsored by Allergan)

  3. PLANET: A randomized, double-masked, sham-controlled phase 3b/4 study of the efficacy, safety, and tolerability of intravitreal aflibercept monotherapy compared to aflibercept with adjunctive photodynamic therapy as indicated in subjects with polypoidal choroidal vasculopathy (Aflibercept) - completed 2018 (Sponsored by Bayer AG)

  4. EVEREST2: A 24-month, phase IV, randomized, double masked, multicenter study of ranibizumab monotherapy or ranibizumab in combination with verteporfin photodynamic therapy on visual outcome in patients with symptomatic macular polypoidal choroidal vasculopathy - completed 2017 (Sponsored by Novartis International AG)

 

Contact information

Email: vitreoretinal@hku.hk
Phone: (852) 3962 1405
Address: Room 301, Level 3 Block B, Cyberport 4 100 Cyberport Road, Hong Kong